MannKind's Afrezza Demonstrates A1c Control In Diabetes Patients During MannKind's Phase 4 Trial
MannKind's Afrezza Demonstrates A1c Control In Diabetes Patients During MannKind's Phase 4 Trial
曼恩凱德生物醫療的Afrezza在曼恩凱德生物醫療的第4階段試驗中展示了對糖尿病患者的A1c控制能力
MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced top-level 30-week results from its Phase 4 INHALE-3 study, in which additional patients living with type 1 diabetes achieved target A1c levels during the extension phase. The completer analysis which included all people on inhaled insulin, evaluated two separate groups – one that utilized Afrezza (plus basal insulin) over 30 weeks, and a second group of patients who switched to Afrezza at week 17 from usual care, defined as multiple daily injections (MDI), an automated insulin delivery...
曼恩凱德生物醫療公司（NASDAQ:MNKD）是一家專注於開發和商業化吸入治療產品和設備，用於治療內分泌和孤兒肺部疾病患者的公司。其今日宣佈了第4階段INHALE-3研究30周的高級結果，該研究顯示在...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間